Pancreatic Cancer Research

ResearcherKeimyung UniversityActive in the last 2 years

Dong Joon Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7035-087X; OpenAlex author ID A5100617949. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. First author DOI 10.4014/jmb.2412.12032↗
  2. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2015.05.017↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Won‐Jun Jang · 1 shared paper, 2025 · strength 0.33
  2. Seongjun Park · 1 shared paper, 2025 · strength 0.33
  3. Chul‐Ho Jeong · 1 shared paper, 2025 · strength 0.33
  4. Dong-Hwan Kim · 1 shared paper, 2025 · strength 0.33
  5. Mi‐Ju Kim · 1 shared paper, 2015 · strength 0.04
  6. Seung‐Mo Hong · 1 shared paper, 2015 · strength 0.04
  7. Young Il Yeom · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.